RT Journal Article
SR Electronic
T1 Genome-wide meta-analysis of iron status biomarkers and the effect of iron on all-cause mortality in HUNT
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.20.21262960
DO 10.1101/2021.09.20.21262960
A1 Moksnes, Marta R
A1 Hansen, Ailin Falkmo
A1 Graham, Sarah E
A1 Gagliano Taliun, Sarah A
A1 Wu, Kuan-Han
A1 Zhou, Wei
A1 Thorstensen, Ketil
A1 Fritsche, Lars G
A1 Gill, Dipender
A1 Mason, Amy
A1 Cucca, Francesco
A1 Schlessinger, David
A1 Abecasis, Gonçalo R.
A1 Burgess, Stephen
A1 Åsvold, Bjørn Olav
A1 Nielsen, Jonas B
A1 Hveem, Kristian
A1 Willer, Cristen J
A1 Brumpton, Ben M
YR 2021
UL http://medrxiv.org/content/early/2021/09/23/2021.09.20.21262960.abstract
AB Iron is essential for many biological processes, but iron levels must be tightly regulated to avoid harmful effects of both iron deficiency and overload. Here, we perform genome-wide association studies on four iron related biomarkers (serum iron, serum ferritin, transferrin saturation, total iron binding capacity) in the Trøndelag Health Study (HUNT), the Michigan Genomics Initiative (MGI) and the SardiNIA study, followed by their meta-analysis with publicly available summary statistics, analyzing up to 257 953 individuals. We identify 127 genetic loci associated with iron traits. Among 19 novel protein-altering variants, we observe a rare missense variant (rs367731784) in HUNT, which suggests a role for DNAJC13 in transferrin recycling. We further validate the latest genetic risk scores for each biomarker in HUNT (6% variance in serum iron explained) and present linear and non-linear Mendelian randomization analyses of the traits on all-cause mortality. We find evidence of a harmful effect of increased serum iron and transferrin saturation in linear analyses that estimate population-averaged effects. However, there was weak evidence of a protective effect of increasing serum iron at the very low end of its distribution. Our findings contribute to our understanding of the genes affecting iron status and its consequences on human health.Competing Interest StatementD.G is employed part-time by Novo Nordisk outside the submitted work. G.R.A. works for Regeneron Pharmaceuticals. C.J.W.'s spouse works for Regeneron Pharmaceuticals. The remaining authors have no competing interests to declare.Funding StatementThe Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research Center (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genotyping in HUNT was financed by the National Institutes of Health; University of Michigan; the Research Council of Norway; the Liaison Committee for Education, Research, and Innovation in Central Norway; and the Joint Research Committee between St Olav's hospital and the Faculty of Medicine and Health Sciences, NTNU.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study participants have given informed consent. The analyses in HUNT has approval from the Norwegian Data Protection Authority and the Regional Ethics Committee for Medical and Health Research Ethics in Central Norway (REK Reference Number: 2014/144), the analyses in MGI are approved by the Institutional Review Board of the University of Michigan Medical School (IRB Reference Number: HUM00094409), and the analyses in UK Biobank are covered by the ethics approval for UK Biobank studies (application 24460) from the NHS National Research Ethics Service on 17th June 2011 (Ref 11/NW/0382) and extended on 10th May 2016 (Ref 16/NW/0274).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData generated or analyzed during this study are available from the corresponding authors upon reasonable request.